Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (30192)	1/13/2000 9:50:00 AM
From: Torben Noerup Nielsen	Read Replies (2) \| Respond to of 32384

Look, if Targretin and Ontak sales take off, then Panretin isn't all that important. Some drugs are simply flops. The good news in this case is that as far as I can tell, the market has already - based on reactions to previous news regarding the sales - discounted the value of Panretin to approximately 0. So it really isn't in the price any longer. If it turns out to contribute, that's good. If it doesn't, it shouldn't hurt any more. Discounting Panretin is one of the reasons for the drop we saw some time ago. Cheers, Torben